News
Stay Ahead with the Latest Industry Trends & Market Insights with Industry News 📰

Morquio Syndrome Therapy Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: November 2023 || SKU: PH7214
excelpdfpowerpoint
180 pages
Report Summary
Table of Contents
List of Tables & Figures
Get Free Sample

See how US Tariffs impact Morquio Syndrome Therapy Market

Morquio Syndrome Therapy Market is segmented By Type (Enzyme Replacement Therapy, Supportive/Symptomatic Therapy, Others) By Therapy (MPS IV Type A, MPS IV Type B), By Route of Administration (Injectable, Oral, Other), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

 

Morquio Syndrome Therapy Market Overview

The Global Morquio Syndrome Therapy Market is expected to reach at a CAGR during the forecast period 2023-2030.

Morquio syndrome is a infrequent genetic disorder impacting a child’s bones and spine, organs, and physical capabilities. Kids with this disorder are deficient or do not produce sufficient amounts of the enzymes that metabolizes sugar chains inherently produced in the body. These chains stockpile in cells, blood, tendons, and ligaments, inducing wear and trear over time. In 2014, the FDA authorized a recombinant human GALNS enzyme replacement therapy (elosulfase alfa, or Vimizim) for the treatment of MPS IVA while other therapy of MPS IV is symptomatic and supportive.

Morquio Syndrome Therapy Market Scope

Metrics

Details

CAGR

High

Market Size Available for Years

2021-2030

Estimation Forecast Period

2023-2030

Revenue Units

Value (US$ Mn) 

Segments Covered

Type, Therapy, Route of Administration, Distribution Channel, and Region

Regions Covered

North America, Europe, Asia-Pacific, South America, and Middle East & Africa

Largest Region

North America

Fastest Growing Region

Asia-Pacific

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights.

 

To Know More Insights - Download Sample

 

Morquio Syndrome Therapy Market Dynamics

Authorizations From Regulatory Bodies

The new approvals for the existing Morquio Syndrome therapy and increasing support from distinct regulatory authorities are expected to boost the global market growth during the forecast period. For instance, in June 2019, BioMarin Pharmaceutical Inc. obtained the National Medical Products Administration (NMPA) approval for its Vimizim (elosulfase alfa) in the treatment of individuals with mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. Vimizim is the first treatment in China approved for this condition.

Moreover, the NICE in March 2022, issued the conclusive draft guidance suggesting elosulfase alfa (also called Vimizin and made by BioMarin) for recurring usage in the NHS for the therapy of mucopolysaccharidosis type 4A (also known as MPS 4A and Morquio A syndrome). Furthermore, the increasing research activities, growing awareness and plrevalence are also expected to boost the global market growth during the forecast period.

High Therapy Cost 

The high cost of the therapy is expected to hamper the global market growth during the forecast period. For instance, the cost of elosulfase alfa in few nations is in beyween $2,080,000 to $6,240,000 per year, making  it problematic for some health plans to afford it. Furthermore, the low treatment choices, low prevalence and high drug development costs are also expected to hamper the global market growth during the forecast period.

Morquio Syndrome Therapy Market Segment Analysis

The global morquio syndrome therapy market is segmented based on type, therapy, route of administration, distribution channel and region.

MPS IV Type A is Expected to Dominate Market

Owing to the increase in positive research investigation outcomes and high prevalence of MPS IV Type A than MPS IV Type B, it is estimated to dominate the global market during the forecast period. For instance, a team at the Universitat Autònoma de Barcelona (UAB), Spain, has developed the first rat model summarizing all disabling alterations encountered by individuals with Mucopolysaccharidosis type IVA, also termed Morquio A disease. The team has even created a gene therapy that fully restores the extreme whole-body alterations in the rat model after a single intravenous viral vector administration, opening the door to a prospective therapy that might be administered at young ages in patients detected with this rare disease, thereby averting bone malformations, osteoarthritic intricacies, and other life-threatening alterations. 

Moreover, according to the National Organization for Rare Disorders, Inc. MPS IVA is detected in 95% of individuals impacted by MPS IV while MPS IVB is detected in around 5% of affected individuals.

Morquio Syndrome Therapy Market Geographical Share

North America is Expected to Dominate the Global Market

Owing to the increase research initiatives and funding are expected to boost the North American market, dominating the global market during the forecast period. For instance, in May 2023, as a component of the Foundation for the National Institutes of Health (FNIH) Accelerating Medicines Partnership Bespoke Gene Therapy Consortium (AMP BGTC), Nemours Children's Health has been picked to execute a first-of-its-kind gene therapy clinical trial for Morquio A syndrome.

Again, in August 2023, a unique initiative strives to eliminate hindrance, delivering $97 million in funds and expertise to assist investigators in testing gene therapy in individuals with Morquio and seven other ultrarare diseases as soon as next year. The program, a coalition of nonprofits, government, and industry, is directed by the non-profit Foundation for the National Institutes of Health. Furthermore, the growing awareness and prevalence of the condition is also contributing to the regional market growth during the forecast period.  

COVID-19 Impact Analysis

Enzyme replacement therapy (ERT) is a common treatment for certain types of lysosomal storage diseases (LSDs), which involves intravenously administering weekly or biweekly doses. ERT has been found to improve respiratory and cardiac function, alleviate organomegaly, improve range of motion, and enhance the overall health-related quality of life for some types of mucopolysaccharidoses (MPS). 

However, the global market growth for scheduled ERT was negatively affected due to COVID-19 disruptions. Lysosomal storage diseases are high-risk illnesses because of their involvement with respiratory, renal, and cardiac functions. The COVID-19 pandemic has also disrupted the availability of ERT, which has had a significant impact on the global market growth.

Key Developments

  • In March 2022, the National Institute for Health and Care Excellence (NICE) issued conclusive draft guidance recommending the recurring use of elosulfase alfa, also known as Vimizin and produced by BioMarin, for the treatment of mucopolysaccharidosis type 4A (MPS 4A) or Morquio A syndrome in the NHS.
  • In 2019, Vimizim (elosulfase alfa) by BioMarin Pharmaceutical Inc. has received approval from the National Medical Products Administration (NMPA) to treat patients with mucopolysaccharidosis type IVA (MPS IVA) or Morquio A syndrome. This marks the first ever approved treatment for this rare condition in China.

Morquio Syndrome Therapy Market Companies

The major global players in the market include BioMarin, JCR Pharmaceuticals Co., Ltd., Novartis AG, Takeda Pharmaceutical Company Limited., Alexion Pharmaceuticals, Inc., Regenxbio Inc., Ultragenyx Pharmaceutical Inc., Abbvie Inc., and Abeona Therapeutics Inc. among others.

Why Purchase the Report?

  • To visualize the global morquio syndrome therapy market segmentation based on type, therapy, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development. 
  • Excel data sheet with numerous data points of morquio syndrome therapy market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global morquio syndrome therapy market report would provide approximately 69 tables, 67 figures and 192 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies
FAQ’s

  • The segments are By Type, By Therapy, By Route of Administration, By Distribution Channel, and By Region.

  • Key players are BioMarin, JCR Pharmaceuticals Co., Ltd., Novartis AG, Takeda Pharmaceutical Company Limited., Alexion Pharmaceuticals, Inc., Regenxbio Inc., Ultragenyx Pharmaceutical Inc., Abbvie Inc., and Abeona Therapeutics Inc. among others.

  • Asia Pacific is the fastest-growing region in the Morquio Syndrome Therapy Market.

  • North America is the Largest Market Share in Morquio Syndrome Therapy Market.
Related Reports
pharmaceuticals iconpharmaceuticals

Metachromatic leukodystrophy Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 November 18

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Phosphoglucomutase (PGM 1) Deficiency Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: 2023 September 19

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Bloom Syndrome Treatment Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: 2023 November 15

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Usher Syndrome Treatment Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: 2023 October 06

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Chronic Bronchitis Treatment Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: 2024 December 18

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Penile Cancer Treatment Market Size, Share, Forecast and Outlook (2024-2031)

Published: 2023 September 26

Starting from

$4350

WhatsApp